Patent SG-11201908833T-A (SG)
Title: Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
Inventor: THROSBY MARK
IPC: C07K16/32
Filed: 2018-04-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT o mons °nolo ono! mu HE Imo oimIE (10) International Publication Number WO 2018/182421 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/46 (2006.01) C07K 16/28 (2006.01) C07K 16/30 (2006.01) CO7K 16/32 (2006.01) (21) International Application Number: PCT/NL2018/050205 (22) International Filing Date: Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164396.8 31 March 2017 (31.03.2017) EP 15/476,260 31 March 2017 (31.03.2017) US (71) Applicant: MERUS N.V. [NL/NL]; Yalelaan 62, 3584 CM Utrecht (NL). (72) Inventors: THROSBY, Mark; c/o Yalelaan 62, 3584 CM Utrecht (NL). GEUIJEN, Cecilia Anna Wilhelmina; c/o Yalelaan 62, 3584 CM Utrecht (NL). MAUSSANG-DE- TAILLE, David Andre Baptiste; c/o Yalelaan 62, 3584 CM Utrecht (NL). LOGTENBERG, Ton; c/o Yalelaan 62, 3584 CM Utrecht (NL). (74) Agent: JANSEN, CM.; V.O., Carnegieplein 5, 2517 KJ Den Haag (NL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, • KM, ML, MR, NE, SN, TD, TG). 1-1 (54) Title: ERBB-2 TARGETING AGENT AND A BISPECIFIC ANTIBODY WITH ANTIGEN-BINDING SITES THAT BIND co AN EPITOPE ON AN EXTRACELLULAR PART OF ERB-2 AND ERBB-3, FOR TREATMENT OF AN INDIVIDUAL WITH AN ERBB-2, ERBB-2/ERBB-3 POSITIVE TUMOUR (57) : The invention relates among others to antibodies comprising a first antigen- binding site that binds ErbB-2 and a second C:::;) antigen-binding site that binds ErbB- 3. The antibodies can typically reduce a ligand-induced receptor function of ErbB-3 on a ErbB-2 N and ErbB-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of C subjects having an ErbB-2, ErbB-3 or ErbB-2/3 positive tumor.